The therapeutic application of Crinone Gel is relevant in clinical settings that involve acute or unstable symptom patterns related to heightened systemic burden.

Its primary use is in conditions characterized by periods of heightened symptoms, commonly applied in addressing Assisted Reproductive Technology (ART) procedures for supportive relief. It is also used across domains where additional symptomatic support is needed in contexts such as secondary amenorrhea (the temporary absence of a period).

This supportive application helps ease the overall symptom load. The gel is considered relevant for easing symptoms associated with acute or episodic changes, particularly those that interfere with daily functioning across these two primary indications. In these clinical scenarios, it supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Relief for symptoms related to systemic imbalance

Regulatory References

1. NIH MedlinePlus Drug Information on Progesterone Vaginal

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Women requiring progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment program [FDA Labeling].
• Treatment for secondary amenorrhea (absence of menstrual period) [Health Canada].

Populations for whom use is contraindicated:

• Patients with a known hypersensitivity to progesterone or any component of the gel [EMA SmPC].
• Known or suspected hormone-dependent malignancy, such as breast or genital tract carcinoma [FDA Labeling].
• Active or history of thromboembolic disorders (e.g., blood clots, stroke, pulmonary embolism) [EMA SmPC].
• Severe hepatic dysfunction or disease [FDA Labeling].

Age-Related Eligibility Rules

• Pediatric Use: Safety and effectiveness have not been established in the pediatric population, and the medicine is not for use in children [Medsafe].
• Geriatric Use: Safety and efficacy have not been established in women aged 65 and over [FDA Labeling].

Condition-Specific Eligibility Rules

• Prohibited Clinical Status: Use is contraindicated in the presence of undiagnosed abnormal vaginal bleeding or a missed or incomplete abortion [FDA Labeling] [EMA SmPC].
• Pregnancy and Lactation Status: Use is permitted during the first trimester of pregnancy only when prescribed as part of an ART regimen; use is not recommended during breastfeeding [EMA SmPC].

Connection to the overall eligibility profile: Regulatory documents strictly define Crinone Gel's use, limiting eligibility to adult women with specific reproductive health conditions. The profile imposes absolute exclusions for patients with a history of blood clots, certain cancers, or severe liver impairment, and prohibits use when specific clinical signs, such as undiagnosed bleeding, are present. This structure establishes clear regulatory boundaries for the drug's approved population.

Interactions with other medicines and products

The interaction profile for Crinone Gel (progesterone vaginal gel) is primarily characterized by local administration restrictions and a lack of formal systemic drug-drug interaction studies specific to the vaginal formulation, as documented in regulatory sources.

Administration-Timing Restrictions

The most significant documented constraint involves other locally applied products. Co-administration with other local intravaginal therapies is officially restricted. Crinone Gel should not be administered simultaneously with any other products inserted into the vagina. If concurrent use of another local intravaginal therapy is required, the official prescribing information mandates an at least six-hour period of separation before or after the administration of Crinone Gel. This is necessary to maintain the integrity and efficacy of the bioadhesive delivery system.

Systemic and Metabolic Interactions

No formal systemic drug-drug interaction studies have been performed with the Crinone vaginal gel formulation. While the active ingredient, progesterone, is known to be metabolized by the CYP3A4 enzyme, regulatory assessments indicate that no significant clinical consequences on progesterone plasma concentrations are expected from the concurrent administration of the vaginal gel with CYP3A enzyme inducers. Interactions with food, alcohol, or herbal products are not specified in the official regulatory documentation.

Crinone Gel delivers the steroid hormone progesterone, an active substance that exerts its effects through two primary pathways: genomic and non-genomic receptor-mediated signaling. The gel formulation ensures continuous local and systemic exposure to the target tissues. The genomic cascade is initiated as progesterone binds to and activates nuclear progesterone receptors (nPR-A and nPR-B) within the cell cytoplasm. This hormone-receptor complex subsequently dimerizes and translocates to the nucleus, binding to specific DNA Progesterone Response Elements (PREs). This action modifies gene transcription, regulating protein synthesis. The resulting physiological effect is the transformation of the proliferative endometrium into a secretory endometrium. Simultaneously, non-genomic signaling involves rapid, non-classical actions independent of gene transcription, often mediated by membrane progesterone receptors (mPRs). This rapid signaling event activates intracellular sequences, such as the MAPK or Src kinase pathways, leading to a swift adjustment of cellular responses, including the modulation of smooth muscle contractile activity in the uterus.

Official Administration Guidelines and Dosage

Crinone Gel is formulated exclusively for intravaginal administration using a pre-filled, single-use bioadhesive applicator. The medicine is supplied in two official strengths: 45 mg (4% gel) and 90 mg (8% gel) of progesterone.

Labeled Dosing Regimens

Administration Instructions and Restrictions

To apply, the gel is inserted deep into the vagina while the patient is in a sitting or lying position with bent knees; the applicator is designed to deliver a specific dose and must be discarded after a single use. Due to the bioadhesive delivery system, Crinone Gel should not be used concurrently with other vaginal products. If a dose is missed, patients should continue with the next scheduled dose; doubling the dose to compensate for the missed amount is not recommended.

Research evidence / Overview of studies for Crinone Gel

Evidence for use in Assisted Reproductive Technology (ART)

The primary body of evidence for Crinone Gel is derived from clinical trials investigating its role as progesterone supplementation during Assisted Reproductive Technology (ART) procedures, such as In Vitro Fertilization (IVF). These studies are mostly Randomized Controlled Trials (RCTs), alongside large-scale meta-analyses that combine data from multiple trials.

Researchers monitored outcomes related to fertility treatments, specifically tracking measures like the clinical pregnancy rate and the live birth rate. Studies reported measurements of both rates in research that tracked outcomes for the vaginal gel alongside outcomes for other progesterone formulations. The research highlights changes measured during the study period related to specific endometrial changes, such as histological transformation.

Evidence for use in Secondary Amenorrhea

Controlled trials and pharmacodynamic studies have explored the use of Crinone Gel in women experiencing secondary amenorrhea—the absence of a period due to hormonal changes. These studies were designed to evaluate the gel's influence on the uterine lining's expected cycle transformation.

The research examined women who were first prepared with estrogen, and subsequently tracked the measured outcomes following the application of the progesterone. The main outcomes tracked were the physiological transformation of the uterine lining and the occurrence of expected withdrawal bleeding. Studies report how symptoms evolved in the observed populations, indicating that researchers observed the occurrence of withdrawal bleeding in the majority of estrogen-primed participants.

What is still uncertain about Crinone Gel

While the research describes patterns related to the gel's use in the studied conditions, several gaps and limitations exist. One area of uncertainty relates to the optimal length of time for the gel's use in the luteal phase; data provides limited insight into this duration.

Furthermore, follow-up durations were limited in these studies. Research is still ongoing to fully characterize long-term cycle regulation in secondary amenorrhea and to characterize long-term outcomes for children born following exposure in ART. Data remain limited for certain special populations, such as very young or elderly women.

Key Studies & References

1. Progesterone Vaginal Drug Information (NIH MedlinePlus)

Common questions about Crinone Gel (FAQ)

Q: Why is Crinone Gel administered vaginally instead of being a pill?

A: Crinone is specifically formulated as a bioadhesive vaginal gel with sustained-release properties. This delivery system is designed to allow for a prolonged and continuous absorption of the progesterone hormone. Official regulatory documents indicate that this delivery system is used to support the endometrium and provide the necessary hormonal support over time.

Q: Does the application of Crinone Gel feel messy, and how can I clarify what is normal discharge?

A: According to official patient information, it is common to see small, white globules or pieces of the gel appear as vaginal discharge. This appearance is common and is related to the accumulation and subsequent expulsion of the non-active gel base. This occurrence is described in regulatory materials and may happen several days after application.

Q: Is Crinone Gel still considered appropriate for women over the age of 40?

A: Official regulatory sources indicate that progesterone administration has been studied in women across different age groups. Clinical data has shown that the drug can produce expected endometrial responses in women even through the sixth decade of life. Final determination regarding the appropriateness of use is made by the prescribing healthcare professional.

Q: Why is it important for the gel to stay in place after application?

A: Crinone Gel is manufactured using a bioadhesive delivery system, which means it is designed to stick to the vaginal wall to ensure sustained release of the progesterone. For this reason, official patient information indicates that concurrent use of other products inserted into the vagina is restricted, as they may interfere with the gel’s efficacy and ability to stay in place.

Q: What are the reported success rates of Crinone Gel in clinical trials?

A: Studies track specific outcomes related to the drug's approved uses. For example, clinical trial data for Assisted Reproductive Technology (ART) document specific live birth rates and clinical pregnancy rates in study participants. Official documentation contains a summary of the clinical trial outcomes.

Q: How does the official literature describe the benefits compared to no treatment?

A: Official regulatory reviews describe clinical trials primarily designed to compare Crinone Gel against other established progesterone formulations. The measured clinical outcomes are assessed in comparison to other existing treatments or established success rates for the medical condition.

Q: Do official documents mention anything about using Crinone Gel with other fertility treatments?

A: The official prescribing information indicates that Crinone Gel is used as progesterone supplementation for patients undergoing Assisted Reproductive Technology (ART) procedures, including In Vitro Fertilization (IVF). Use in other specific fertility treatment protocols, outside of the official indication, is not addressed in the prescribing information.

Q: Is Crinone Gel the same as other progesterone suppositories?

A: Crinone is distinct because it is formulated as a bioadhesive gel, which is a key component of its sustained-release delivery system. The official descriptions confirm the gel form is designed to allow for a prolonged absorption profile, which is a characteristic of this specific delivery system.

Q: What are some common reasons a patient might discontinue use of Crinone Gel?

A: A key reason for discontinuation, as described in official warnings, is when serious conditions, such as the formation of blood clots, are suspected. Official warnings for progestational drugs note that these are serious potential events that may prompt an immediate review by a healthcare professional.

Q: What are the known potential serious side effects of Crinone Gel that people discuss?

A: According to official regulatory documents, progestational drugs have been associated with reports of serious health problems, including the formation of blood clots. These potential events can lead to complications such as stroke, heart attack, or blood clots in the lungs. Medical attention is necessary if symptoms related to these serious conditions are suspected.

Q: Can Crinone Gel cause changes in mood or make a person feel emotional?

A: Official safety summaries list certain changes in emotional state as potential effects. These reported side effects may include symptoms such as mood swings, irritability, and excessive worrying. Depression is also mentioned in the official product information.

Q: How long does the progesterone from Crinone Gel stay in the body after application?

A: The gel’s sustained-release mechanism means that the progesterone is released into the body over an extended period. Pharmacokinetic studies show that the absorption half-life for the progesterone from the gel is approximately 25 to 50 hours.

Q: Do studies suggest that Crinone Gel is related to an increased risk of blood clots?

A: Official regulatory information acknowledges that blood clots have been reported in association with the use of progestational drugs. The official label notes that patients with certain risk factors for blood clots may require specific observation.

Q: What should a patient do if they see what looks like old gel residue coming out?

A: The appearance of small, white gel accumulation is a noted feature of the product, as described in official patient information. However, the label strongly emphasizes the importance of seeking medical attention immediately if a patient suspects symptoms of a serious condition, such as a blood clot.

Q: Why do some people refer to Crinone Gel as 'progesterone in oil'?

A: The official description of the drug’s components indicates that the gel is formulated as an oil-in-water emulsion. The base contains certain lipid ingredients, such as mineral oil and hydrogenated palm oil glyceride, which likely contributes to the common user description of it containing 'oil.'

Q: Can the absorption of Crinone Gel be affected by physical activity?

A: The official prescribing information does not provide specific guidance regarding the impact of general physical activity on the gel’s absorption. However, some research has suggested that sexual intercourse may lead to a temporary reduction in the level of progesterone measured in the blood.

Q: What are the non-active ingredients in Crinone Gel, and are they a concern?

A: The official label lists the non-active ingredients (excipients), which include mineral oil, glycerin, polycarbophil, and others. Official regulatory documents specify that use is contraindicated in individuals with a known sensitivity or allergy to any of the listed ingredients.

Q: What is the typical time frame for the gel to be absorbed after application?

A: Pharmacokinetic studies show the time it takes for the progesterone concentration in the blood to reach its peak. Following a single dose, pharmacokinetic studies indicate the maximum progesterone concentration is reached in approximately 5.4 to 7.0 hours.

Q: How is the progesterone dose in Crinone Gel determined by regulatory agencies?

A: The approved doses were established based on clinical studies reviewed by regulatory agencies. These studies were specifically designed to identify the amount of progesterone needed to achieve and maintain the minimum blood concentration required to support the uterine lining (endometrium) for the intended treatments.

Q: What are the contraindications listed on the official drug label?

A: Official regulatory sources list specific conditions that preclude the use of Crinone Gel. These contraindications include known sensitivity to any ingredients, undiagnosed vaginal bleeding, pre-existing liver disease or dysfunction, and known or suspected malignant tumors of the breast or genital organs. These are the key exclusions listed on the official drug label.

Q: Is Crinone Gel safe to use if a person is breastfeeding?

A: Limited available information suggests that the amount of progesterone hormone passed to an infant through breast milk is small. Most studies indicate progesterone is generally considered not detrimental to milk production, though specific data on the Crinone Gel formulation during lactation are limited.

Q: What is the meaning of the term 'micronized progesterone' in the context of Crinone Gel?

A: The official description specifies that the active ingredient is micronized progesterone. This term means the progesterone is processed into very small particles. These fine particles are then suspended within the gel's oil and water emulsion, which aids the drug's absorption after application.

Q: What kind of doctor typically prescribes Crinone Gel?

A: Crinone Gel is officially indicated for conditions like Assisted Reproductive Technology (ART) support and secondary amenorrhea. Official indications suggest the medication is generally prescribed by physicians specializing in reproductive endocrinology, infertility, and obstetrics/gynecology.

How to Store and Dispose of Crinone Gel?

Crinone gel requires specific storage conditions to maintain its stability and effectiveness, as documented in official regulatory labeling.

Storage Requirements

• Temperature: Store the product below 25 C (controlled room temperature). Do not freeze the gel.
• Protection: Keep the medicine in its original container/box to protect it from heat and moisture. Do not store it in environments like a bathroom or near a sink.
• Child Safety: It is mandatory to keep the gel out of sight and reach of children.

Handling and Disposal

• Handling: The medication is provided in a single-use, prefilled applicator. The applicator and any remaining gel must be discarded immediately after use.
• Disposal: Do not dispose of Crinone gel in household trash or flush it down the toilet. Expired, damaged, or leftover medicine must be returned to a pharmacist or doctor for proper and environmentally responsible disposal through a medication take-back program.